S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula. Primary endpoints Percent change from BL in body weight at Week 12 Change from BL in ...
CHICAGO – A multimodal, artificial intelligence (AI)-driven model that analyzes routinely collected imaging and clinical information led to more accurate prediction of cancer cachexia than standard ...
Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss leading to progressive functional impairment. Despite the ubiquity of cachexia in clinical practice, prevention, ...
Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...
New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...
Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results